Fig. 3: PFS and OS in patients treated with odronextamab, for all patients and by best overall response. | Nature Cancer

Fig. 3: PFS and OS in patients treated with odronextamab, for all patients and by best overall response.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Fig. 3: PFS and OS in patients treated with odronextamab, for all patients and by best overall response.The alternative text for this image may have been generated using AI.

a, PFS. b, OS. Data are presented as Kaplan–Meier curves, with tick marks indicating patients with censored data (N = 127 patients; n = 40 with CR, n = 26 with PR). Median values with 95% CIs are presented alongside the respective curves.

Source data

Back to article page